Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sound waves target kidney fat to lower stubborn blood pressure

NCT ID NCT07232966

Disease control Sponsor: Yan Li Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether focused power ultrasound can safely lower blood pressure in people with resistant hypertension (high blood pressure that doesn't respond to three or more drugs). About 220 adults will receive either the ultrasound treatment or a sham procedure. The main goal is to see if the treatment reduces average 24-hour systolic blood pressure after 6 months, while also monitoring for side effects like heart attack or kidney problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 220 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2025

An estimate. Start dates often move.

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female participants aged 18-75 years old; 2. 24h ambulatory systolic BP ≥130mmHg and \<150mmHg, and 24h ambulatory diastolic BP \<100mmHg after at least 4 weeks of combined treatment with 3 antihypertensive drugs (including a diuretic); 3. The ultrasound measured inferior perirenal adipose tissue ≥8 cm3 (with the superior-inferior diameter, left-right diameter, and anterior-posterior diameter all needing to be ≥20 mm); 4. Be willing to participate in the trial, and be able to visit doctors by himself or herself; 5. Sign the informed consent form. Exclusion Criteria: 1. Secondary hypertension; 2. Occurrence of myocardial infarction, malignant arrhythmia, severe renal failure, or stroke within 6 months; 3. Ambulatory BP monitoring was invalid (\<70% valid readings, or \<20 daytime readings or \<7 nighttime readings); 4. Alanine transaminase (ALT), aspartate transaminase (AST), or total bilirubin (TBL) above twice the normal range; eGFR (CKD-EPI) \<45mL/min/1.73m2; 5. Type 1 diabetes mellitus or uncontrolled Type 2 diabetes mellitus (glycated hemoglobin ≥8.5%); 6. Single functionally normal kidney or presence of renal malignant tumor; 7. Bilateral skin diseases at renal region that are not suitable for the therapy; 8. Women in pregnancy, lactating, or planning for pregnancy; 9. Other concomitant diseases that are considered not suitable for participation in the trial; 10. Patients have contraindications to angiotensin receptor-neprilysin inhibitor (ARNIs), thiazide-like diuretic drugs, or calcium channel blocker (CCBs); 11. Non-compliant patients.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Resistant hypertension are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

resistant hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Resistant hypertension

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ruijin Hospital

    Shanghai, Shanghai Municipality, 200025, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.